114 research outputs found

    KINEMATICS OF ASSISTED AND RESISTED SPRINTING AS COMPARED TO NORMAL FREE SPRINTING IN TRAINED ATHLETES

    Get PDF
    The purpose of this study was to examine the kinematics of sprinting under assisted (or overspeed) and resisted conditions as compared to normal sprinting during the acceleration and top-speed phases of a sprint. SIX volunteer subjects completed 3 trials of each of 4 conditions: assisted sprinting (AS); free sprinting (FS); resisted sprinting (RS); and, sprint start (SS). One trial per subject per condition was randomly selected for kinematic analysis. Video (60 Hz) was collected in the sagittal plane for two full strides and analysed in 2D using an 8-point, 6-segment model with APAS software. Statistical analysis found no significant differences between AS and FS for any kinematic parameters. No significant differences were found between RS and SS for any kinematic parameters. AS differed significantly (

    Caractérisation de sources de résistance à la fusariose chez le blé dur

    Get PDF
    National audienceFacing the increasing problem of Fusarium head blight with durum wheat caused by different species of Fusarium, a study was undertaken with the help of the Ministry in charge for agriculture. This study made it possible to assess the resistance of different sub-species of Triticum turgidum. The populations with the most resistant accessions belong to the sub-species T. turgidum dicoccum. Going deeper into this study showed that this resistance was a type 2 one: slow progression of necrosis after contamination of one spikelet per spike. One accession, TRI2215, exhibited very high level of resistance, but it is very high and very late accession, this will make this accession difficult to be used in breeding. This justifies a QTL search for Fusarium resistance. The analysis of the determinant for Fusarium aggressiveness confirmed that a great part was linked with the production of mycotoxins. Several phenol compounds seemed to play a part in the resistance of the plant. A qualitative analysis of the Fusarium flora on the spikes allowed identifying six major Fusarium species and to associate them with the different mycotoxins. A close genus, Microdochium, did not produce mycotoxins. We also showed that the amount of mycotoxins in an organ was related to the fungus DNA in the organ.Face au problème croissant chez le blé dur de la fusariose des épis causée par différentes espèces de Fusarium sp., une étude a été entreprise, avec le concours du Ministère chargé de l’Agriculture. Cette étude a permis d’évaluer la résistance de différentes sous-espèces de Triticum turgidum. Les populations contenant le plus d’individus résistants sont issues de la sous-espèce T. turgidum dicoccum. Une étude plus approfondie a permis de montrer cette résistance était de type 2 : faible progression des symptômes après la contamination d’un épillet par épi. Un géniteur, TRI2215, montre un niveau de résistance particulièrement intéressant, mais est très haut et très tardif, ce qui le rendra difficile à utiliser. C’est pourquoi une recherche de QTL a été entreprise sur ce géniteur. L’analyse des déterminants de l’agressivité des Fusarium confirme qu’elle vient en grande partie des mycotoxines. Différents composés phénoliques semblent aussi jouer un rôle dans la résistance de la plante. Une analyse qualitative de la flore fusarienne des épis a permis d’identifier six espèces majeures de Fusarium et de les associer avec les différentes mycotoxines, et qu’un genre proche, Microdochium, ne produisait pas de mycotoxines. Il a montré aussi que la quantité de mycotoxines dans un organe était proportionnelle à la quantité d’ADN du champignon dans l’organe

    Long Term Stabilization of Expanding Aortic Aneurysms by a Short Course of Cyclosporine A through Transforming Growth Factor-Beta Induction

    Get PDF
    Abdominal aortic aneurysms (AAAs) expand as a consequence of extracellular matrix destruction, and vascular smooth muscle cell (VSMC) depletion. Transforming growth factor (TGF)-beta 1 overexpression stabilizes expanding AAAs in rat. Cyclosporine A (CsA) promotes tissue accumulation and induces TGF -beta1 and, could thereby exert beneficial effects on AAA remodelling and expansion. In this study, we assessed whether a short administration of CsA could durably stabilize AAAs through TGF-beta induction. We showed that CsA induced TGF-beta1 and decreased MMP-9 expression dose-dependently in fragments of human AAAs in vitro, and in animal models of AAA in vivo. CsA prevented AAA formation at 14 days in the rat elastase (diameter increase: CsA: 131.9±44.2%; vehicle: 225.9±57.0%, P = 0.003) and calcium chloride mouse models (diameters: CsA: 0.72±0.14 mm; vehicle: 1.10±0.11 mm, P = .008), preserved elastic fiber network and VSMC content, and decreased inflammation. A seven day administration of CsA stabilized formed AAAs in rats seven weeks after drug withdrawal (diameter increase: CsA: 14.2±15.1%; vehicle: 45.2±13.7%, P = .017), down-regulated wall inflammation, and increased αSMA-positive cell content. Co-administration of a blocking anti-TGF-beta antibody abrogated CsA impact on inflammation, αSMA-positive cell accumulation and diameter control in expanding AAAs. Our study demonstrates that pharmacological induction of TGF-beta1 by a short course of CsA administration represents a new approach to induce aneurysm stabilization by shifting the degradation/repair balance towards healing

    COMPASS identifies T-cell subsets correlated with clinical outcomes.

    Get PDF
    Advances in flow cytometry and other single-cell technologies have enabled high-dimensional, high-throughput measurements of individual cells as well as the interrogation of cell population heterogeneity. However, in many instances, computational tools to analyze the wealth of data generated by these technologies are lacking. Here, we present a computational framework for unbiased combinatorial polyfunctionality analysis of antigen-specific T-cell subsets (COMPASS). COMPASS uses a Bayesian hierarchical framework to model all observed cell subsets and select those most likely to have antigen-specific responses. Cell-subset responses are quantified by posterior probabilities, and human subject-level responses are quantified by two summary statistics that describe the quality of an individual's polyfunctional response and can be correlated directly with clinical outcome. Using three clinical data sets of cytokine production, we demonstrate how COMPASS improves characterization of antigen-specific T cells and reveals cellular 'correlates of protection/immunity' in the RV144 HIV vaccine efficacy trial that are missed by other methods. COMPASS is available as open-source software

    Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1

    Get PDF
    Patients with biallelic loss-of-function variants of AIRE suffer from autoimmune polyendocrine syndrome type-1 (APS-1) and produce a broad range of autoantibodies (auto-Abs), including circulating auto-Abs neutralizing most type I interferons (IFNs). These auto-Abs were recently reported to account for at least 10% of cases of life-threatening COVID-19 pneumonia in the general population. We report 22 APS-1 patients from 21 kindreds in seven countries, aged between 8 and 48 yr and infected with SARS-CoV-2 since February 2020. The 21 patients tested had auto-Abs neutralizing IFN-α subtypes and/or IFN-ω; one had anti–IFN-β and another anti–IFN-ε, but none had anti–IFN-κ. Strikingly, 19 patients (86%) were hospitalized for COVID-19 pneumonia, including 15 (68%) admitted to an intensive care unit, 11 (50%) who required mechanical ventilation, and four (18%) who died. Ambulatory disease in three patients (14%) was possibly accounted for by prior or early specific interventions. Preexisting auto-Abs neutralizing type I IFNs in APS-1 patients confer a very high risk of life-threatening COVID-19 pneumonia at any age.publishedVersio

    Autoantibodies against type I IFNs in patients with critical influenza pneumonia

    Full text link
    In an international cohort of 279 patients with hypoxemic influenza pneumonia, we identified 13 patients (4.6%) with autoantibodies neutralizing IFN-alpha and/or -omega, which were previously reported to underlie 15% cases of life-threatening COVID-19 pneumonia and one third of severe adverse reactions to live-attenuated yellow fever vaccine. Autoantibodies neutralizing type I interferons (IFNs) can underlie critical COVID-19 pneumonia and yellow fever vaccine disease. We report here on 13 patients harboring autoantibodies neutralizing IFN-alpha 2 alone (five patients) or with IFN-omega (eight patients) from a cohort of 279 patients (4.7%) aged 6-73 yr with critical influenza pneumonia. Nine and four patients had antibodies neutralizing high and low concentrations, respectively, of IFN-alpha 2, and six and two patients had antibodies neutralizing high and low concentrations, respectively, of IFN-omega. The patients' autoantibodies increased influenza A virus replication in both A549 cells and reconstituted human airway epithelia. The prevalence of these antibodies was significantly higher than that in the general population for patients 70 yr of age (3.1 vs. 4.4%, P = 0.68). The risk of critical influenza was highest in patients with antibodies neutralizing high concentrations of both IFN-alpha 2 and IFN-omega (OR = 11.7, P = 1.3 x 10(-5)), especially those <70 yr old (OR = 139.9, P = 3.1 x 10(-10)). We also identified 10 patients in additional influenza patient cohorts. Autoantibodies neutralizing type I IFNs account for similar to 5% of cases of life-threatening influenza pneumonia in patients <70 yr old

    Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths

    Get PDF
    Publisher Copyright: © 2021 The Authors, some rights reserved.Circulating autoantibodies (auto-Abs) neutralizing high concentrations (10 ng/ml; in plasma diluted 1:10) of IFN-alpha and/or IFN-omega are found in about 10% of patients with critical COVID-19 (coronavirus disease 2019) pneumonia but not in individuals with asymptomatic infections. We detect auto-Abs neutralizing 100-fold lower, more physiological, concentrations of IFN-alpha and/or IFN-omega (100 pg/ml; in 1:10 dilutions of plasma) in 13.6% of 3595 patients with critical COVID-19, including 21% of 374 patients >80 years, and 6.5% of 522 patients with severe COVID-19. These antibodies are also detected in 18% of the 1124 deceased patients (aged 20 days to 99 years; mean: 70 years). Moreover, another 1.3% of patients with critical COVID-19 and 0.9% of the deceased patients have auto-Abs neutralizing high concentrations of IFN-beta. We also show, in a sample of 34,159 uninfected individuals from the general population, that auto-Abs neutralizing high concentrations of IFN-alpha and/or IFN-omega are present in 0.18% of individuals between 18 and 69 years, 1.1% between 70 and 79 years, and 3.4% >80 years. Moreover, the proportion of individuals carrying auto-Abs neutralizing lower concentrations is greater in a subsample of 10,778 uninfected individuals: 1% of individuals 80 years. By contrast, auto-Abs neutralizing IFN-beta do not become more frequent with age. Auto-Abs neutralizing type I IFNs predate SARS-CoV-2 infection and sharply increase in prevalence after the age of 70 years. They account for about 20% of both critical COVID-19 cases in the over 80s and total fatal COVID-19 cases.Peer reviewe
    corecore